Healthcare Digest
Weekly curated insights from healthcare, pharma, and biotech. Stay informed on pharmacy billing, NDC updates, and industry trends.
Pharmacy Industry Newsletter
Get weekly insights on pharmacy billing, NDC updates, and revenue optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime.
Novartis hit by 2 late-stage trial failures
PLUS: Ionis wins FDA approval for Alexander disease therapy and pancreatic cancer patients face treatment access barriersIonis wins first FDA nod for Alexander disease
PLUS: Xenotransplant patients get human kidneys, lung cancer drug tops Keytruda, and Ultragenyx cuts costs after trial failureNovartis, BMS halt autoimmune CAR-T trials on safety
PLUS: Lilly's Mounjaro wins CV nod, Takeda scores rare cancer approval, and a $2.9B immunology buyoutRevolution's pancreatic cancer drug wins FDA approval
PLUS: AstraZeneca's heart drug failure raises class concerns, Cytokinetics scores cardiomyopathy win, Priovant lands rare disease nodCourt backs Medicare drug pricing vs. Merck, AZ
PLUS: FDA halts Regenxbio gene therapy again, RFK Jr. seeks vaccine input, Moderna-Merck cancer vaccine successModerna-Merck cancer vaccine posts landmark Phase 3 win
PLUS: Ultragenyx scores first gene therapy approval, Regeneron wins FDA nod for ultra-rare bone disease, Trump taps Overton for FDA chiefBMS wins first CELMoD drug approval for myeloma
PLUS: Amylyx scores with GLP-1 blocker, Argenx expands Vyvgart franchise, and IRS probes UnitedHealthLilly sues 6 firms over retatrutide black market
PLUS: Psychedelic pill shows promise for anxiety, Neurocrine faces safety concerns, and Commure halts AI referral paymentsTrump orders overhaul of pediatric vaccine schedule
PLUS: Jazz acquires epilepsy drugmaker for $1.3B, Sionna's cystic fibrosis drug fails trial, FDA mandates food additive noticesFDA approves first mRNA flu vaccine from Moderna
PLUS: Replimune wins melanoma therapy approval after two rejections, Takeda's first-in-class narcolepsy drug, and a clinical trial death in ChinaCurium Acquires Lantheus for $8B in Radiopharma Deal
PLUS: BioNTech names new CEO, AstraZeneca-BMS merger speculation heats up, and Amgen reports major cybersecurity breachJ&J bets $2.6B on in vivo CAR-T tech
PLUS: FDA panel backs Replimune's melanoma therapy, Medicaid work rules proceed, FTC sues Hims & HersSarepta taps ex-AbbVie exec Severino as new CEO
PLUS: Argenx's $2.2B Forte acquisition, FDA approves Otsuka's ADHD drug Simtriyo, and Alzheimer's trial shows safety promiseFDA panel backs unapproved peptides in narrow vote
PLUS: GSK's lung cancer drug approval, Lilly's obesity treatment advances, and Trump's generic drug tariff threatNovo sues Lilly over GLP-1 ads; Tempus buys for $1.5B
PLUS: Bristol Myers builds AI supercomputer, Samsung Biologics eyes peptide maker, and telehealth safety concerns emergeMerck wins FDA nod for first oral PCSK9 pill
PLUS: Lilly's $2.8B psychedelics bet, Medicare's AI payment overhaul, and prediction markets hit clinical trialsPadcev-Keytruda Combo Wins FDA Nod for Bladder Cancer
PLUS: Sanofi's first on-body injector for cancer, FDA's Zyn authorization under scrutiny, and a pancreatic cancer breakthroughAstraZeneca, Ionis heart drug fails Phase 3 trial
PLUS: FDA approves Vera's kidney disease treatment, White House reviews FDA commissioner finalists, and Roche ends Huntington's programsVertex acquires Crinetics for $10B in biotech boom
PLUS: FDA expands gene therapy to toddlers, telehealth GLP-1 prescriptions lack oversight, and Amgen recalls nearly 1M heart medication bottlesRoche KRAS drug beats rival in lung cancer trial
PLUS: FDA approves Orca Bio's cell therapy, Anthropic enters drug development, and Colorado's price cap blocked26 States Sue to Block Medicaid Work Requirements
PLUS: FDA approvals reshape TED and gout markets, Zymeworks acquires Theravance for $929M, and AstraZeneca settles kickback chargesSupreme Court Overturns Roundup Cancer Verdict
PLUS: Gilead's Trodelvy wins FDA approval for triple-negative breast cancer, Merck KGaA acquires Bio-Techne for $11.3B, WHO launches Ebola treatment trialAbbVie Bets $11B on Apogee's Autoimmune Pipeline
PLUS: China approves first CAR-T for solid tumors, Lilly cuts 340B discounts, and FDA reverses gene therapy rejectionModerna's mRNA flu shot wins FDA panel backing
PLUS: Ebola outbreak escalates in Africa, gene therapy advances for Huntington's disease, and biotech IPO market heats upFDA Approves Colorado's Canada Drug Import Plan
PLUS: Medicare targets subcutaneous cancer drugs, Merck wins kidney cancer approval, AI transforms neurology trialsParabilis breaks IPO record with $670M raise
PLUS: Takeda's psoriasis drug beats Bristol Myers in head-to-head trial, Novartis RNA therapy succeeds, Medicare Advantage plans face scrutinyRXDELTA Healthcare Digest
Trump strips job protections from NIH leadership
PLUS: Ebola treatment access authorized amid research cuts, ADC Therapeutics trial deaths, Supreme Court skinny label rulingRevolution's RAS drug shows unprecedented pancreatic results
PLUS: Trump overhauls vaccine schedule, ASCO delivers multiple cancer breakthroughs, Ebola vaccine funding acceleratesGSK hepatitis B drug achieves functional cure in 20%
PLUS: CVS restores Lilly obesity drug coverage, AstraZeneca faces FDA delay, and blood pressure wearables flood marketAstraZeneca's Datroway Wins FDA Nod for Breast Cancer
PLUS: Lilly expands vaccine portfolio, Biogen's Parkinson's setback, and new FDA leadership takes chargeLilly's Triple-G Drug Matches Bariatric Surgery Results
PLUS: Merck-Kelun lung cancer combo slashes progression 65%, Biogen's Parkinson's setback, and Bristol Myers goes all-in on AIWHO declares Ebola emergency; U.S. bans travel
PLUS: Supreme Court upholds Medicare drug negotiations, Maryland caps Ozempic prices, and AstraZeneca wins FDA approvalsRegenxbio's Duchenne gene therapy heads to FDA
PLUS: FDA leadership search narrows, BeOne wins lymphoma approval, and Lilly-Novo obesity battle heats upTrump to Fire FDA Chief Makary
PLUS: Roche acquires AI pathology firm for $750M, Lilly invests $4.5B in manufacturing, Supreme Court extends mifepristone accessSanofi pulls drug from FDA program after interference
PLUS: Novo's Wegovy pill hits $355M debut, Angelini buys Catalyst for $4.1B, and FDA blocks vaccine safety studiesSupreme Court restores mifepristone access
PLUS: FDA approves first PROTAC cancer drug, UCB acquires bispecifics maker for $2.2B, hantavirus outbreak on cruise shipPurdue Pharma to Dissolve After Criminal Sentence
PLUS: Trump names new surgeon general nominee, AI outperforms doctors in diagnostics, and $2.6B in pharma dealsSun Pharma's $11.75B Organon Buyout Tops 2026 Deals
PLUS: Intellia's CRISPR therapy succeeds in pivotal trial, Lilly acquires two innovation-focused companies, and FDA fast-tracks psychedelic treatmentsFDA Approves Regeneron Gene Therapy for Hearing Loss
PLUS: Trump's drug pricing deals, Merck's $1B Google AI partnership, and AbbVie's $1.4B North Carolina campusTrump orders FDA to fast-track psychedelics review
PLUS: Lilly acquires cell therapy firm for $3.25B, CAR-T shows promise in preventing myeloma, and Revolution Medicines' KRAS dataKailera nets $625M in massive obesity drug IPO
PLUS: Lilly's oral obesity pill clears heart safety hurdle, Roche plans new Elevidys trial, Novartis CEO joins AI boardMerck acquires Terns for $6.7B in oncology bet
PLUS: FDA approves rare disease therapies for Hunter syndrome and ovarian cancer, medical schools drop equity requirementsPfizer's Lyme vaccine moves forward despite mixed data
PLUS: FDA expands Rhythm's obesity drug, Parkinson's med safety updates, and 22,000+ pharma job cuts in 2025Lilly's triple-G obesity drug hits Phase 3 milestone
PLUS: Novo's high-dose Wegovy wins FDA approval, J&J's oral psoriasis pill clears regulatory hurdles, and NIH funding crisis deepensJudge blocks RFK Jr. vaccine policy overhaul
PLUS: Oral GLP-1 pill shows promising weight loss results, GSK expands RSV vaccine, and White House pushes most-favored nation drug pricingFDA Launches Unified Safety Surveillance System
PLUS: Lilly warns of impurities in GLP-1 knockoffs, commits $3B to China manufacturing, and MedPAC calls out Medicare Advantage overpaymentsVinay Prasad Exits FDA as Biotech Stocks Rally
PLUS: BioNTech founders launch new mRNA venture, Novo strikes Hims deal, and Vertex kidney drug succeeds in trialLilly bypasses insurers with employer GLP-1 program
PLUS: Moderna settles COVID vaccine patent fight for $2.25B, FDA cracks down on compounded weight loss drugsCMS Halts Elevance Medicare Advantage Enrollment
PLUS: FDA approves Ascendis dwarfism drug, UniQure gene therapy setback, AI chatbot gets breakthrough statusLilly's GLP-1 pill beats Novo's Rybelsus in Phase 3
PLUS: FDA faces Senate scrutiny on rare disease reviews, Sarepta CEO announces retirement, and Generate raises $400M in IPONovo's Obesity Drug Fails Against Lilly's Zepbound
PLUS: Gilead's $7.8B Arcellx buy, FDA's gene therapy roadmap, and Merck's oncology splitDOJ sues OhioHealth over anticompetitive contracts
PLUS: Grail's cancer test misses study goal, Supreme Court strikes down tariffs, and Vertex's CRISPR therapy reboundsFDA reverses course on Moderna's flu vaccine review
PLUS: New standard for drug approvals, psilocybin heads to FDA, and Grail's cancer test setbackDigital Health Integration Transforms Modern Pharmacy Practice
PLUS: AI clinical tools gain traction, remote patient monitoring expands, and pharmacy apps reshape patient engagementHarm reduction programs gain ADA legal protections
PLUS: AstraZeneca targets 25+ blockbusters by 2030, fentanyl smoking linked to fewer overdoses, Hims faces regulatory scrutinyBiosimilar Adoption Surges as Patents Expire on Major Biologics
PLUS: New adalimumab biosimilar enters market, oncology biosimilar pipeline expands, and payer formulary shifts accelerateNew CMS Rules Reshape 340B Program Oversight for 2026
PLUS: Hospital outpatient drug spending surges, insulin pricing update, and pharmacy quality measure changesIndependent Pharmacies Fight Back Against PBM Practices
PLUS: FTC releases damning PBM report, state attorney general actions, and pharmacy coalition gains momentumFDA Accelerates Generic Drug Approvals in Push for Lower Prices
PLUS: New compounding regulations proposed, telepharmacy expansion, and specialty drug pipeline updateCVS Health Restructuring Plan Shakes Up Retail Pharmacy Landscape
PLUS: Walgreens explores going private, generic drug pricing trends, and pharmacy technician shortage deepensWhat's Ahead for Pharmacy in 2026: Trends and Predictions
PLUS: New year drug launches, reimbursement outlook, and technology trends to watchPharmacy Industry Year in Review: The Biggest Stories of 2025
PLUS: Top drug launches, regulatory milestones, and what shaped pharmacy practice this yearMedicare Part D Changes Bring Relief for Seniors' Drug Costs in 2026
PLUS: Pharmacy deserts expand, biosimilar Humira gains market share, and new antibiotic wins FDA approvalEli Lilly's Weight-Loss Drug Expansion Signals New Era in Obesity Treatment
PLUS: Novo Nordisk supply chain update, pharmacy benefit reform advances, and CVS earnings surprise